Telesta Therapeutics $26.40 million Financing. Donald Olds Published Aug 26 D form
Telesta Therapeutics Financing
Telesta Therapeutics Inc., Corporation just submitted form D for $26.40 million equity financing. This is a new filing. Telesta Therapeutics was able to fundraise $26.40 million. That is 100.00% of the fundraising. The total financing amount was $26.40 million. The fundraising form was filed on 2015-08-26. The reason for the financing was: unspecified.
Telesta Therapeutics is based in Ontario – Canada. The company’s business is Biotechnology. The D form was filed by Donald Olds Chief Operating Officer and Corporate Secretary. The company was incorporated more than five years ago. The filler’s address is: 231 Dundas Street East, Belleville, A6, Ontario, Canada, K8n 1E2. Michael Joseph Berendt is the related person in the form and it has address: 231 Dundas Street East, Belleville, A6, Ontario, Canada, K8n 1E2. Link to Telesta Therapeutics Filing: 000157104915007038.
Analysis of Telesta Therapeutics Offering
On average, companies in the Biotechnology sector, sell 73.77% of the total offering amount. Telesta Therapeutics sold 100.00% of the offering. Could this mean that the trust in Telesta Therapeutics is high? The average offering size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 757.14% bigger than the average for companies in the Biotechnology sector. The minimum investment for this financing is set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Telesta Therapeutics Also
The Form D signed by Donald Olds might help Telesta Therapeutics Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.